Colonic supply of vasoactive intestinal peptide nanomedicine alleviates colitis and reveals promise as an oral capsule
Goal: To guage the efficacy of domestically delivered nanomedicine, vasoactive intestinal peptide in sterically stabilized micelles (VIP-SSM) to the colon and conduct in vitro launch research of a possible oral formulation.
Supplies & strategies: Intracolonic instillation of VIP-SSM was examined in a mouse mannequin of dextran sulfate sodium-induced colitis. Based mostly on the efficient mouse dose, human equal dose containing nanomedicine powder was stuffed into enteric coated capsules for in vitro launch testing.
Outcomes: Colonic supply of VIP-SSM considerably alleviated colitis. VIP-SSM containing capsules utterly dissolved at colonic pH permitting micelles to reform with lively VIP. Capsule formulations exhibited reproducible launch profiles when saved as much as 6 weeks demonstrating stability.
Conclusion: VIP-SSM is an efficient nanomedicine formulation which seems to have potential for oral therapy of colitis in people.
antibodysource
JAG-1, scrambled |
|||
| MBS5789393-INQUIRE | MyBiosource | INQUIRE | Ask for price |
JAG-1, scrambled |
|||
| TP1686-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: JAG-1, scrambled |
|||
JAG-1, scrambled |
|||
| TP1686-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: JAG-1, scrambled |
|||
JAG-1, scrambled |
|||
| TP1686-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: JAG-1, scrambled |
|||
JAG-1, scrambled |
|||
| TP1686-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: JAG-1, scrambled |
|||
JAG-1, scrambled |
|||
| TP1686-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: JAG-1, scrambled |
|||
Human NEP1-40 of Nogo-66 peptide, Scrambled peptide control for NEP140, >95% pure |
|||
| NEP140-115 | Alpha Diagnostics | 100 ug | 343.2 EUR |
Human NEP1-40 of Nogo-66 peptide Scrambled peptide control for NEP140 >95% pure |
|||
| NEP140-115-1000 | Alpha Diagnostics | 1000 ug | 927.6 EUR |
Scrambled shRNA Control Lentivirus |
|||
| LSV-0024-1S | LipExoGen | 2x10^6 | 395 EUR |
|
Description: vsv-g |
|||
Scrambled shRNA Control Lentivirus |
|||
| LSV-0024-2S | LipExoGen | 2x10^6 | 395 EUR |
|
Description: vsv-g |
|||
Scrambled shRNA Control Lentivirus |
|||
| LSV-0024-3S | LipExoGen | 2x10^6 | 395 EUR |
|
Description: vsv-g |
|||
Scrambled shRNA Control Lentivirus |
|||
| LSV-0024-4S | LipExoGen | 2x10^6 | 395 EUR |
|
Description: vsv-g |
|||
Scrambled shRNA Control Lentivirus |
|||
| LSV-0024-5S | LipExoGen | 2x10^6 | 395 EUR |
|
Description: vsv-g |
|||
Scrambled shRNA Control Lentivirus |
|||
| LSV-0024-6S | LipExoGen | 2x10^6 | 395 EUR |
|
Description: vsv-g |
|||
Scrambled shRNA Control Lentivirus |
|||
| LSV-0024-7S | LipExoGen | 2.5x10^6 | 395 EUR |
|
Description: vsv-g |
|||
Scrambled shRNA Control Lentivirus |
|||
| LSV-0024-8S | LipExoGen | 2.5x10^6 | 395 EUR |
|
Description: vsv-g |
|||
LL-37 scrambled peptide |
|||
| HY-P1513 | MedChemExpress | 1mg | 418.8 EUR |
LL-37 scrambled peptide |
|||
| MBS5763833-1mg | MyBiosource | 1mg | 260 EUR |
LL-37 scrambled peptide |
|||
| MBS5763833-5mg | MyBiosource | 5mg | 760 EUR |
LL-37 scrambled peptide |
|||
| MBS5763833-5x5mg | MyBiosource | 5x5mg | 3265 EUR |
LL-37 scrambled peptide |
|||
| TP1825-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: LL-37 scrambled peptide |
|||
LL-37 scrambled peptide |
|||
| TP1825-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: LL-37 scrambled peptide |
|||
LL-37 scrambled peptide |
|||
| TP1825-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: LL-37 scrambled peptide |
|||
LL-37 scrambled peptide |
|||
| TP1825-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: LL-37 scrambled peptide |
|||
LL-37 scrambled peptide |
|||
| TP1825-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: LL-37 scrambled peptide |
|||
Scrambled TRAP Fragment Peptide |
|||
| 20-abx265858 | Abbexa |
|
|
Scrambled TRAP Fragment Peptide |
|||
| abx265858-200tests | Abbexa | 200 tests | 225 EUR |
Scrambled TRAP Fragment Peptide |
|||
| abx265858-500tests | Abbexa | 500 tests | 312.5 EUR |
Scrambled-peptide Knockdown Control Cell Line Expressing Dendra2 |
|||
| T6521 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
JAG-1, scrambled TFA (402941-23-5 free base) |
|||
| MBS5765434-10mg | MyBiosource | 10mg | 335 EUR |
JAG-1, scrambled TFA (402941-23-5 free base) |
|||
| MBS5765434-25mg | MyBiosource | 25mg | 545 EUR |
JAG-1, scrambled TFA (402941-23-5 free base) |
|||
| MBS5765434-2mg | MyBiosource | 2mg | 210 EUR |
JAG-1, scrambled TFA (402941-23-5 free base) |
|||
| MBS5765434-50mg | MyBiosource | 50mg | 780 EUR |
JAG-1, scrambled TFA (402941-23-5 free base) |
|||
| MBS5765434-5mg | MyBiosource | 5mg | 255 EUR |
JAG-1, scrambled TFA(402941-23-5 free base） |
|||
| TP1686L-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: JAG-1, scrambled TFA(402941-23-5 free base） |
|||
JAG-1, scrambled TFA(402941-23-5 free base） |
|||
| TP1686L-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: JAG-1, scrambled TFA(402941-23-5 free base） |
|||
JAG-1, scrambled TFA(402941-23-5 free base） |
|||
| TP1686L-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: JAG-1, scrambled TFA(402941-23-5 free base） |
|||
JAG-1, scrambled TFA(402941-23-5 free base） |
|||
| TP1686L-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: JAG-1, scrambled TFA(402941-23-5 free base） |
|||
JAG-1, scrambled TFA(402941-23-5 free base） |
|||
| TP1686L-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: JAG-1, scrambled TFA(402941-23-5 free base） |
|||
sgp91 ds-tat Peptide 2, scrambled |
|||
| MBS5789300-INQUIRE | MyBiosource | INQUIRE | Ask for price |
sgp91 ds-tat Peptide 2, scrambled |
|||
| TP1585-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: sgp91 ds-tat Peptide 2, scrambled |
|||
sgp91 ds-tat Peptide 2, scrambled |
|||
| TP1585-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: sgp91 ds-tat Peptide 2, scrambled |
|||
sgp91 ds-tat Peptide 2, scrambled |
|||
| TP1585-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: sgp91 ds-tat Peptide 2, scrambled |
|||
sgp91 ds-tat Peptide 2, scrambled |
|||
| TP1585-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: sgp91 ds-tat Peptide 2, scrambled |
|||
sgp91 ds-tat Peptide 2, scrambled |
|||
| TP1585-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: sgp91 ds-tat Peptide 2, scrambled |
|||
3-D Life Scrambled RGD Peptide |
|||
| 09-P-003 | Cellendes | 1 µmol | 121 EUR |
3-D Life Scrambled RGD Peptide |
|||
| P11-3 | Cellendes | 3x 1 µmol | 330 EUR |
PGMtide Control Peptide |
|||
| 040-70 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Scrambled shRNA Control THP-1 Cell Line (With GFP) -Polyclone |
|||
| T9790 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
L201 pLVPTH2- tTR- KRAB- Cerulean- scrambled- shRNA- Control |
|||
| PVT11122 | Lifescience Market | 2 ug | 361.2 EUR |
Scrambled Cathelicidin antimicrobial peptide 18 |
|||
| SB010 | Smartox Biotechnology | 1 | 134.41 EUR |
|
Description: Scrambled LL-37 has the same peptide sequence as LL-37 but loses helixforming property.Scrambled LL-37 can be used as a negative control of LL-37 studies. |
|||
JAG-1 Protein Active Peptide Fragment |
|||
| 080-11 | PHOENIX PEPTIDE | 100 μg | 129.6 EUR |
PGMtide Control Peptide - Cy3 Labeled |
|||
| FC3-040-70 | PHOENIX PEPTIDE | 1 nmol | 925.56 EUR |
PGMtide Control Peptide - FAM Labeled |
|||
| FG-040-70A | PHOENIX PEPTIDE | 5 nmol | 537.84 EUR |
PGMtide Control Peptide - Biotin Labeled |
|||
| B-040-70 | PHOENIX PEPTIDE | 20 μg | 537.84 EUR |
PGMtide Control Peptide - Rhodamine Labeled |
|||
| FR-040-70 | PHOENIX PEPTIDE | 5 nmol | 604.8 EUR |
Human, mouse, rat connexin 43 and 37 scrambled peptide (GAP27 domain) |
|||
| Cx2704-PS-1 | Alpha Diagnostics | 1 mg | 315.6 EUR |
Human, mouse, rat connexin 43 and 37 scrambled peptide (GAP27 domain) |
|||
| Cx2704-PS-5 | Alpha Diagnostics | 5 mg | 927.6 EUR |
Human, mouse, rat connexin 37/40 hemi-channel Scrambled peptide (GAP26 domain) |
|||
| Cx2602-PS-1 | Alpha Diagnostics | 1 mg | 343.2 EUR |
Human, mouse, rat connexin 37/40 hemi-channel Scrambled peptide (GAP26 domain) |
|||
| Cx2602-PS-5 | Alpha Diagnostics | 5 mg | 927.6 EUR |
ZIP (SCRAMBLED) |
|||
| A8830-1 | ApexBio | 1 mg | 74.4 EUR |
|
Description: TGF-β / Smad Signaling|PKC |
|||
PADRE scrambled |
|||
| SB084 | Smartox Biotechnology | 1 | 81.81 EUR |
|
Description: SB-peptide offers the scrambled version of PADRE peptide. AAATLWKAAKFVA can be used as a negative control of PADRE peptide studies.SB-peptide offers also PADRE peptide (see section PADRE peptide).PADRE peptide: Pan HLA DR-binding epitope is a universal peptide that activates antigen specific-CD4+ T cells which can be used as an agonist adjuvant in immunotherapeutic vaccine development. Pan HLA DR-binding epitope has been proposed as a carrier epitope suitable for use in the development of synthetic and recombinant vaccines. It has been demonstrated that PADRE may be an universal approach to control tumor cells. Moreover, PADRE is also used in research about an immunosense approach to develop a base for development of vaccines against toxoplasmosis to protect person with HLA-A*03 type. Pan HLA DR-binding epitope can be also used as tool to study the autoreactive T cell response. |
|||
Scrambled 10Panx |
|||
| A2701-1 | ApexBio | 1 mg | 40 EUR |
|
Description: Neuroscience|Gap Junction#Membrane Transporter/Ion Channel|Pannexin-1#Other Signal Transduction |
|||
Scrambled 10Panx |
|||
| A2701-10 | ApexBio | 10 mg | 144 EUR |
|
Description: Neuroscience|Gap Junction#Membrane Transporter/Ion Channel|Pannexin-1#Other Signal Transduction |
|||
Scrambled 10Panx |
|||
| A2701-25 | ApexBio | 25 mg | 320 EUR |
|
Description: Neuroscience|Gap Junction#Membrane Transporter/Ion Channel|Pannexin-1#Other Signal Transduction |
|||
Scrambled 10Panx |
|||
| A2701-5 | ApexBio | 5 mg | 80 EUR |
|
Description: Neuroscience|Gap Junction#Membrane Transporter/Ion Channel|Pannexin-1#Other Signal Transduction |
|||
Scrambled 10Panx |
|||
| MBS3840702-10mg | MyBiosource | 10mg | 235 EUR |
Scrambled 10Panx |
|||
| MBS3840702-25mg | MyBiosource | 25mg | 430 EUR |
Scrambled 10Panx |
|||
| MBS3840702-5mg | MyBiosource | 5mg | 165 EUR |
Scrambled 10Panx |
|||
| MBS3840702-5x25mg | MyBiosource | 5x25mg | 1920 EUR |
LL-37 (scrambled) |
|||
| 4099707.05 | Bachem | 0.5 mg | 195.51 EUR |
LL-37 (scrambled) |
|||
| 4099707.1 | Bachem | 1 mg | 317.94 EUR |
LL-37 (scrambled) |
|||
| H-7886.0500 | Bachem | 0.5mg | 339.6 EUR |
|
Description: Sum Formula: C205H340N60O53; CAS# [1354065-56-7] net |
|||
LL-37 (scrambled) |
|||
| H-7886.1000 | Bachem | 1.0mg | 529.2 EUR |
|
Description: Sum Formula: C205H340N60O53; CAS# [1354065-56-7] net |
|||
ZIP (SCRAMBLED) Acetate |
|||
| MBS5773250-1mg | MyBiosource | 1mg | 190 EUR |
ZIP (SCRAMBLED) Acetate |
|||
| MBS5773250-2mg | MyBiosource | 2mg | 235 EUR |
ZIP (SCRAMBLED) Acetate |
|||
| MBS5773250-5mg | MyBiosource | 5(mg | 300 EUR |
ZIP (SCRAMBLED) Acetate |
|||
| T22175L-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: ZIP (SCRAMBLED) Acetate |
|||
ZIP (SCRAMBLED) Acetate |
|||
| T22175L-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: ZIP (SCRAMBLED) Acetate |
|||
ZIP (SCRAMBLED) Acetate |
|||
| T22175L-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: ZIP (SCRAMBLED) Acetate |
|||
ZIP (SCRAMBLED) Acetate |
|||
| T22175L-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: ZIP (SCRAMBLED) Acetate |
|||
ZIP (SCRAMBLED) Acetate |
|||
| T22175L-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: ZIP (SCRAMBLED) Acetate |
|||
Scrambled TRAP Fragment |
|||
| 5-01910 | CHI Scientific | 4 x 5mg | 155.61 EUR |
|
Description: Phe-Ser-Leu-Leu-Arg-Asn-NH2 |
|||
Scrambled TRAP Fragment |
|||
| MBS5799340-5mg | MyBiosource | 5(mg | 915 EUR |
Scrambled TRAP Fragment |
|||
| MBS5799340-5x5mg | MyBiosource | 5x5(mg | 3970 EUR |
Scrambled TRAP Fragment |
|||
| MBS8247030-10mg | MyBiosource | 10mg | 560 EUR |
Scrambled TRAP Fragment |
|||
| MBS8247030-1mg | MyBiosource | 1mg | 225 EUR |
Scrambled TRAP Fragment |
|||
| MBS8247030-5mg | MyBiosource | 5mg | 400 EUR |
Scrambled TRAP Fragment |
|||
| MBS8247030-5x10mg | MyBiosource | 5x10mg | 2435 EUR |
Scrambled TRAP Fragment |
|||
| T38743-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: Scrambled TRAP Fragment |
|||
Scrambled TRAP Fragment |
|||
| T38743-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: Scrambled TRAP Fragment |
|||
Scrambled TRAP Fragment |
|||
| T38743-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: Scrambled TRAP Fragment |
|||
Scrambled TRAP Fragment |
|||
| T38743-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: Scrambled TRAP Fragment |
|||
Scrambled TRAP Fragment |
|||
| T38743-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: Scrambled TRAP Fragment |
|||
OVA 257-264 scrambled |
|||
| SB073 | Smartox Biotechnology | 1 | 81.81 EUR |
|
Description: SB-peptide offers the scrambled version of OVA 257-264. FILKSINE can be used as a negative control of OVA 257-264 studies.SB-peptide offers also OVA 257-264 (see section OVA 257-264).Ovalbumin protein:OVA 257-264 (H-2Kb) is an epitope of interest of the egg white albumen, ovalbumin. Ovalbumin is a glycoprotein that is sufficiently large and complex to be mildly immunogenic. Indeed, it has been demonstrated that Ovalbumin contains B-cell epitopes which are recognized by specific IgE antibodies and CD4 T cell epitopes restricted by the MHC I-Ad molecule in mice and by HLA-D molecule in human.Applications of OVA 257-264:OVA 257-264 is used to stimulate T cells in PBMCs and to quantify peptide epitope specificity and IFN-γ releasing effector cells by ELISPOT assay. OVA 257-264 is also used to test new adjuvant in immunotherapeutic vaccine development. OVA 257-264 can form a stable hydrogel and stimulate a immune response. This reaction seems to be linked with OVA 257-264 property to self-assemble into a hydrogel. Sequence:C45H74N10013 |
|||
Neuropeptide Y (scrambled) |
|||
| B7530-1 | ApexBio | 1 mg | 486 EUR |
|
Description: Scrambled Neuropeptide Y (scNPY) was similarly synthesized and contains the same amino acids as NPY, but scNPY is in a random sequence, it was used as a control in the research in NPY [1]. The sequence of scNPY is SKPQRDANREPTRYAIYDYSNPDIELHYLRPAYALG-NH2 [2]. |
|||
Neuropeptide Y (scrambled) |
|||
| MBS5764161-1mg | MyBiosource | 1mg | 625 EUR |
Neuropeptide Y (scrambled) |
|||
| MBS5764161-5x1mg | MyBiosource | 5x1mg | 2655 EUR |
Neuropeptide Y (scrambled) |
|||
| TP2194-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: Neuropeptide Y (scrambled) |
|||
Neuropeptide Y (scrambled) |
|||
| TP2194-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: Neuropeptide Y (scrambled) |
|||
Neuropeptide Y (scrambled) |
|||
| TP2194-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: Neuropeptide Y (scrambled) |
|||
Neuropeptide Y (scrambled) |
|||
| TP2194-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: Neuropeptide Y (scrambled) |
|||
Neuropeptide Y (scrambled) |
|||
| TP2194-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: Neuropeptide Y (scrambled) |
|||
Amyloid β-Protein (1-42) (scrambled) |
|||
| 4064853.05 | Bachem | 0.5 mg | 317.94 EUR |
Amyloid β-Protein (1-42) (scrambled) |
|||
| 4064853.1 | Bachem | 1 mg | 432.6 EUR |
Amyloid b-Protein (1-42) (scrambled) |
|||
| H-7406.0500 | Bachem | 0.5mg | 529.2 EUR |
|
Description: Sum Formula: C203H311N55O60S; CAS# [1678415-52-5] net |
|||
Amyloid b-Protein (1-42) (scrambled) |
|||
| H-7406.1000 | Bachem | 1.0mg | 706.8 EUR |
|
Description: Sum Formula: C203H311N55O60S; CAS# [1678415-52-5] net |
|||
Amyloid b-Protein (1-40) (scrambled) |
|||
| H-7408.0500 | Bachem | 0.5mg | 402 EUR |
|
Description: Sum Formula: C194H295N53O58S; CAS# [1678415-68-3] net |
|||
Amyloid b-Protein (1-40) (scrambled) |
|||
| H-7408.1000 | Bachem | 1.0mg | 727.2 EUR |
|
Description: Sum Formula: C194H295N53O58S; CAS# [1678415-68-3] net |
|||
Mouse Lipin-1 Control/blocking peptide control/blocking peptide #1 |
|||
| LPN11-P | Alpha Diagnostics | 100 ug | 196.8 EUR |
MAGE-A p248V9 scrambled |
|||
| SB080 | Smartox Biotechnology | 1 | 93.5 EUR |
|
Description: SB-peptide offers the scrambled version of MAGE-A p248V9. RQYVELPYV can be used as a negative control of MAGE-A p248V9 studies.SB-peptide offers also MAGE-A p248V9 (see section MAGE-A p248V9)).MAGE-A protein:MAGE-A p248V9, also kwon as multi-MAGE-A (YLEYRQVPV) is an epitope of Melanoma Antigen Gene expressed by tumors of different histological types and is a Cancer/Testis Antigens (CTA). Type of MAGE-A expressed in tumors cells varies according to the type of tumor. Targeting epitopes shared by all MAGE-A antigens would be interest in immunotherapy against a broad spectrum of cancers. Applications of MAGE-A p248V9 (multi-MAGE-A) :MAGE-A p248V9 is very useful because it could generate an HLA-A*02:01-restricted CTL response and shared by MAGE-A1,-A2,-A3,-A4,-A6,-A10 and -A12. MAGE-A p248V9 is used to stimulate specific cytotoxic T lymphocytes (CTL) in PBMCs and then to analyze CTL response especially the cytokine production by ELISPOT assay.Sequence : RQYVELPYV |
|||
Human MDM2 siRNA (Scrambled) |
|||
| abx941274-150g | Abbexa | 150 µg | 450 EUR |
Human MDM2 siRNA (Scrambled) |
|||
| abx941274-300g | Abbexa | 300 µg | 612.5 EUR |
PAR-2 (1-6) amide (human) (scrambled) |
|||
| H-6428.0025 | Bachem | 25.0mg | 385.2 EUR |
|
Description: Sum Formula: C28H54N8O7; CAS# [1348395-60-7] net |
|||
PAR-2 (1-6) amide (human) (scrambled) |
|||
| H-6428.0100 | Bachem | 100.0mg | 1082.4 EUR |
|
Description: Sum Formula: C28H54N8O7; CAS# [1348395-60-7] net |
|||
Melan-A (26-35) scrambled |
|||
| SB081 | Smartox Biotechnology | 1 | 64.28 EUR |
|
Description: SB-peptide offers the scrambled version of Melan-A/MART-1 (26-35). AIEIAGGLTV can be used as a negative control of Melan-A/MART-1 (26-35) studies.SB-peptide offers also Melan-A/MART-1 (26-35) (see section Melan-A/MART-1 (26-35)).Native Melan-A (26-35) decapepetide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas1.The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide1. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) peptide (EAAGIGILTV), and consequently displays more potent antigenicity and immunogenicity1.It has been reported that the concentration of Melan-A (26-35) A27L analog required to obtain 50% of maximal antigenic activity (EC50) is 0.01nM, whereas that of the native Melan-A (26-35) peptide is 0.25nM1. Therefore, the relative activity of Melan-A (26-35) A27L analog is 25 fold higher than that of the native Melan-A (26-35) peptide. Furthermore, functional competition assay has shown that the concentration of Melan-A (26-35) A27L analog required to achieve 50% inhibition (IC50) of tumor lysis is 2nM, which is 10 fold lower than that of the native Melan-A (26-35) peptide1. Regarding peptide stability in human serum, the half-lifes (t1/2) of the native Melan-A (26-35) peptide and the A27L analog are quite similar (45 and 40min, respectively) as measured by HPLC-ESI-MS, but much higher than that of the Melan-A (27-35) nonapeptide (5min)1.Sequence : AIEIAGGLTV |
|||
MAGE-A2 (157-166) scrambled |
|||
| SB082 | Smartox Biotechnology | 1 | 93.5 EUR |
|
Description: SB-peptide offers the scrambled version of MAGE-A2 (157-166). VLVYFQEIGL can be used as a negative control of MAGE-A2 (157-166) studies.SB-peptide offers also MAGE-A2 (157-166) (see section MAGE-A2 (157-166)).MAGE-A2 protein: MAGE-A2 (157-166) is an epitope of Melanoma Antigen Gene A2 and is one of the most Cancer-Testis Antigens (CTA) overexpressed in tumors of different histological types, such as prostate cancer. Type of MAGE-A expressed in tumors cells varies according to the type of tumor. The expression of MAGE-A2 causes the proliferation of prostate cancer cells and decreases the chemosensitivity. Applications of MAGE-A2 (157-166):MAGE-A2 (157-166) is used to stimulate specific immune response, cytotoxic T cell response and to analyze the cytokine production in PBMCs by ELISPOT assay. In transgenic mouse, it has been demonstrated that MAGE-A2 (157-166) was capable of eliciting a CTL response presented by HLA-A*02:01 molecules. MAGE-A2 (157-166) has been reported to elicit CTL that could lyse tumor cell expressing both HLA-A*02:01 and MAGE-A2 by stimulation of peripheral blood mononuclear cells (PBMCs) with MAGE-A2 (157-166).Sequence : VLVYFQEIGL |
|||
MAGE-A1 (278-286) scrambled |
|||
| SB083 | Smartox Biotechnology | 1 | 93.5 EUR |
|
Description: SB-peptide offers the scrambled version of MAGE-A1 (278-286). ELIVKVYKV can be used as a negative control of MAGE-A1 (278-286) studies.SB-peptide offers also MAGE-A1 (278-286) (see section MAGE-A1 (278-286)).MAGE-A1 protein:MAGE-A1 (278-286) is an epitope of Melanoma Antigen Gene A1 expressed by tumors of different histological types such as on the surface of breast carcinoma cell and is a Cancer/Testis Antigens (CTA). MAGE-A1 is a tumor antigen expressed in 40% of melanoma and contains epitope for binding HLA-A*02:01 molecules and that are recognized by cytotoxic T cells. Applications of MAGE-A1 (278-286): MAGE-A1 (278-286) is used to stimulate specific cytotoxic T cells in PBMCs and to analyze by ELISPOT peptide epitope specificity and cytokine production like IFN-γ. Immunogenicity of MAGE-A1 (278-286) raised the possibility of developing anticancer immunotherapies or vaccinations. MAGE-A1 is also expressed in lung adenocarcinoma and studies suggest that MAGE-A1 may serve to develop Chimeric Antigen Receptor (CAR) T cell therapy using lentiviral vector and show an encouraging tumor-inhibitory efficacy.Sequence : ELIVKVYKV |
|||
Human EGFRviii siRNA (Scrambled) |
|||
| abx941279-150g | Abbexa | 150 µg | 450 EUR |
Human EGFRviii siRNA (Scrambled) |
|||
| abx941279-300g | Abbexa | 300 µg | 612.5 EUR |
Mouse Lipin-2 Control/blocking peptide control/blocking peptide #1 |
|||
| LPN21-P | Alpha Diagnostics | 100 ug | 196.8 EUR |
Mouse Lipin-3 Control/blocking peptide control/blocking peptide #1 |
|||
| LPN31-P | Alpha Diagnostics | 100 ug | 196.8 EUR |
5-FAM-LL-37 (scrambled) |
|||
| 4099708.05 | Bachem | 0.5 mg | 335.9 EUR |
5-FAM-LL-37 (scrambled) |
|||
| 4099708.1 | Bachem | 1 mg | 577.5 EUR |
5-FAM-LL-37 (scrambled) |
|||
| H-7888.0500 | Bachem | 0.5mg | 559.2 EUR |
|
Description: Sum Formula: C226H350N60O59; CAS# [2022972-73-0] net |
|||
5-FAM-LL-37 (scrambled) |
|||
| H-7888.1000 | Bachem | 1.0mg | 931.2 EUR |
|
Description: Sum Formula: C226H350N60O59; CAS# [2022972-73-0] net |
|||
Scrambled sgRNA CRISPR Lentivector |
|||
| K018 | ABM | 1.0 ug | 184.8 EUR |
Amyloid beta-Protein (Human, 1-40) (Scrambled) |
|||
| MBS407587-01mg | MyBiosource | 0.1mg | 215 EUR |
Amyloid beta-Protein (Human, 1-40) (Scrambled) |
|||
| MBS407587-5x01mg | MyBiosource | 5x0.1mg | 915 EUR |
Amyloid beta-Protein (Human, 1-42) (Scrambled) |
|||
| MBS407588-01mg | MyBiosource | 0.1mg | 320 EUR |
Amyloid beta-Protein (Human, 1-42) (Scrambled) |
|||
| MBS407588-5x01mg | MyBiosource | 5x0.1mg | 1385 EUR |
5-FAM-Amyloid β-Protein (1-42) (scrambled) |
|||
| 4099694.01 | Bachem | 0.1 mg | 99.96 EUR |
5-FAM-Amyloid β-Protein (1-42) (scrambled) |
|||
| 4099694.05 | Bachem | 0.5 mg | 359.52 EUR |
Teplow's Amyloid β-Protein (1-40) (scrambled II) |
|||
| 4104167.01 | Bachem | 0.1 mg | 86.52 EUR |
Teplow's Amyloid β-Protein (1-40) (scrambled II) |
|||
| 4104167.05 | Bachem | 0.5 mg | 299.99 EUR |
Teplow's Amyloid β-Protein (1-42) (scrambled II) |
|||
| 4104168.05 | Bachem | 0.5 mg | 299.99 EUR |
Teplow's Amyloid β-Protein (1-42) (scrambled II) |
|||
| 4104168.1 | Bachem | 1 mg | 450.56 EUR |
5-FAM-Amyloid b-Protein (1-42) (scrambled) |
|||
| H-7836.0100 | Bachem | 0.1mg | 192 EUR |
|
Description: Sum Formula: C224H321N55O66S |
|||
5-FAM-Amyloid b-Protein (1-42) (scrambled) |
|||
| H-7836.0500 | Bachem | 0.5mg | 594 EUR |
|
Description: Sum Formula: C224H321N55O66S |
|||
Teplow's Amyloid b-Protein (1-40) (scrambled II) |
|||
| H-8278.0100 | Bachem | 0.1mg | 170.4 EUR |
|
Description: Sum Formula: C194H295N53O58S |
|||
Teplow's Amyloid b-Protein (1-40) (scrambled II) |
|||
| H-8278.0500 | Bachem | 0.5mg | 501.6 EUR |
|
Description: Sum Formula: C194H295N53O58S |
|||
Teplow's Amyloid b-Protein (1-42) (scrambled II) |
|||
| H-8282.0500 | Bachem | 0.5mg | 501.6 EUR |
|
Description: Sum Formula: C203H311N55O60S |
|||
Teplow's Amyloid b-Protein (1-42) (scrambled II) |
|||
| H-8282.1000 | Bachem | 1.0mg | 734.4 EUR |
|
Description: Sum Formula: C203H311N55O60S |
|||
Biotinyl-εAhx-LL-37 (scrambled) |
|||
| 4099709.05 | Bachem | 0.5 mg | 326.97 EUR |
Biotinyl-εAhx-LL-37 (scrambled) |
|||
| 4099709.1 | Bachem | 1 mg | 555.03 EUR |
Biotinyl-eAhx-LL-37 (scrambled) |
|||
| H-7896.0500 | Bachem | 0.5mg | 542.4 EUR |
|
Description: Sum Formula: C221H365N63O56S; CAS# [2022972-72-9] net |
|||
Biotinyl-eAhx-LL-37 (scrambled) |
|||
| H-7896.1000 | Bachem | 1.0mg | 896.4 EUR |
|
Description: Sum Formula: C221H365N63O56S; CAS# [2022972-72-9] net |
|||
NY-ESO-1 (157-165) C165V scrambled (MSILWQLVT) |
|||
| SB079 | Smartox Biotechnology | 1 | 93.5 EUR |
|
Description: SB-peptide offers the scrambled MSILWQLVT peptide that can be used as a negative control of NY-ESO-1 (157-165) C165V variant epitope studies.SB-peptide also offers NY-ESO-1 (157-165) C165V (see section NY-ESO-1 (157-165) C165V). HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQV peptide differes from the New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) native SLLMWITQC peptide, whose protein is part of a well-characterized group of cancer/testis antigens (CTAs).Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) C165V peptide application Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein, including SLLMWITQC, that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members, its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8+ T cells.SB-peptide offers the scrambled MSILWQLVT peptide that can be used as a negative control of NY-ESO-1 (157-165) C165V variant epitope studies.SB-peptide also offers NY-ESO-1 (157-165) C165V (see section NY-ESO-1 (157-165) C165V). HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQV peptide differes from the New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) native SLLMWITQC peptide, whose protein is part of a well-characterized group of cancer/testis antigens (CTAs).Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) C165V peptide application Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein, including SLLMWITQC, that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members, its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8+ T cells.In order to better stimulate specific cytotoxic T-cells in PBMCs and analyze by ELISPOT peptide epitope, specificity, and cytokine production, like IFN-γ, SLLMWITQV variant peptide was used, as it is known to have a higher affinity for the binding cleft of the HLA-A*0201 complex than the native peptide. Moreover, SLLMWITQV has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165) C165V.SB-PEPTIDE also offers NY-ESO-1 (157-165) native peptide, as well as Biotin-NY-ESO-1 (157-165) C165V.In order to better stimulate specific cytotoxic T-cells in PBMCs and analyze by ELISPOT peptide epitope, specificity, and cytokine production, like IFN-γ, SLLMWITQV variant peptide was used, as it is known to have a higher affinity for the binding cleft of the HLA-A*0201 complex than the native peptide. Moreover, SLLMWITQV has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165) C165V.SB-PEPTIDE also offers NY-ESO-1 (157-165) native peptide, as well as Biotin-NY-ESO-1 (157-165) C165V. |
|||
Human Canonical EGFR siRNA (Scrambled) |
|||
| abx941277-150g | Abbexa | 150 µg | 450 EUR |
Human Canonical EGFR siRNA (Scrambled) |
|||
| abx941277-300g | Abbexa | 300 µg | 612.5 EUR |
Tide Fluor 2-LL-37 (scrambled) |
|||
| H-8288.0100 | Bachem | 0.1mg | 374.4 EUR |
|
Description: Sum Formula: C205H340N60O53+dye |
|||
Tide Fluor 2-LL-37 (scrambled) |
|||
| H-8288.0500 | Bachem | 0.5mg | 1220.4 EUR |
|
Description: Sum Formula: C205H340N60O53+dye |
|||
Scrambled sgRNA CRISPR/Cas9 THP-1 Cell Line |
|||
| T9700 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Prion Protein (106-126) (human) (scrambled) |
|||
| 4033124.05 | Bachem | 0.5 mg | 187.64 EUR |
Prion Protein (106-126) (human) (scrambled) |
|||
| 4033124.1 | Bachem | 1 mg | 299.99 EUR |
Prion Protein (106-126) (human) (scrambled) |
|||
| H-4882.0500 | Bachem | 0.5mg | 327.6 EUR |
|
Description: Sum Formula: C80H138N26O24S2; CAS# [150469-23-1] net |
|||
Prion Protein (106-126) (human) (scrambled) |
|||
| H-4882.1000 | Bachem | 1.0mg | 501.6 EUR |
|
Description: Sum Formula: C80H138N26O24S2; CAS# [150469-23-1] net |
|||
Mouse Peptide YY (PYY) control/blocking peptide # 1 |
|||
| PYY11-P | Alpha Diagnostics | 100 ug | 196.8 EUR |
DSL Domain - JAG-1 (Human) |
|||
| 101-01 | PHOENIX PEPTIDE | 100 μg | 430.92 EUR |
RGD Control Peptide |
|||
| MBS566499-5mg | MyBiosource | 5mg | 295 EUR |
RGD Control Peptide |
|||
| MBS566499-5x5mg | MyBiosource | 5x5mg | 1260 EUR |
Tide Fluor™ 2-LL-37 (scrambled) |
|||
| 4104171.01 | Bachem | 0.1 mg | 217.98 EUR |
Tide Fluor™ 2-LL-37 (scrambled) |
|||
| 4104171.05 | Bachem | 0.5 mg | 763.98 EUR |
P2X1, Control Peptide |
|||
| MBS555335-INQUIRE | MyBiosource | INQUIRE | Ask for price |
P2X2, Control Peptide |
|||
| MBS555338-01mg | MyBiosource | 0.1mg | 195 EUR |
The Mitochondrial-Focused Peptide, SS31, Protects Murine 661W Cells from Oxidative Harm by way of Induction of Autophagy
The objective of this examine was to look at the influence of the mitochondrial-targeted antioxidant peptide, SS31, and its function in selling autophagy in cone photoreceptor 661W cells that had been subjected to oxidative harm. To take action, we examined the viability of 661W cells within the presence of accelerating concentrations of H₂O₂ with or with out SS31 pre-treatment utilizing the MTT assay and by expression of autophagy and apoptosis-associated proteins LC3-II/I, P62, and caspase-3.
Autophagy was evaluated by fluorescence microscopy in cells stained with monodansyl cadaverine (MDC). Autophagy was induced with rapamycin (Rap) and inhibited with bafamycin A1 (bafA1) adopted by examination of Reactive oxygen species (ROS) ranges in goal 661W cells by fluorescence microscopy and stream cytometry. Annexin V/PI staining was used to judge the speed of apoptosis and mRNA sequencing (mRNA-seq) evaluation (Illumina platform) was carried out on H₂O₂-exposed 661W cells handled with SS31.
Amongst our outcomes, we noticed a considerable and concentration-dependent lower in 661W cell viability in response to H₂O₂-exposure; manufacturing of ROS, autophagy and apoptosis had been induced at eight h in response to publicity to 100 μM of H₂O₂. Pre-treatment with 100 nM SS31 resulted in important attenuation of H₂O₂-mediated cytotoxicity, along with diminished ROS manufacturing and enhanced autophagy noticed in response to oxidative stress.
Each Rap and bafA1 had been used to modulate SS31-mediated autophagy; the influence of Rap was much like that of SS31. In contrast, administration of bafA1 counteracted autophagy induced by SS31. Moreover, mRNAseq evaluation revealed that SS31 promoted important alterations in gene expression in 661W cells and steered that autophagy was induced by way of the mTORC1-mediated signaling.
In conclusion, our outcomes point out that publicity to H₂O₂ resulted in diminished 661W cell viability by way of mechanisms related to oxidative harm, apoptosis, and autophagy. Notably, we demonstrated that pre-treatment with SS31 protects 661W cells from H₂O₂-induced oxidative harm that will end in half from induction of autophagy by way of mTORC1-mediated signaling pathways.
Reconstitution of an Anti-HER2 Antibody Paratope by Grafting Twin CDR-Derived Peptides Onto a Small Protein Scaffold
Goal-binding small proteins are promising options to traditional monoclonal antibodies (mAbs), providing benefits when it comes to tissue penetration and manufacturing prices. Lately, we developed a design technique to create small proteins known as fluctuation-regulated affinity proteins (FLAPs) consisting of a structurally immobilized peptide from the complementarity-determining area (CDR) loops of mAbs (CDR-derived peptide) and a protein scaffold. As a result of mAb paratopes are often composed of a number of CDRs, FLAPs with a number of binding peptides could have an enhanced target-binding functionality.
Right here, we describe a technique to create FLAPs bearing twin CDR-derived peptides (D-FLAPs) utilizing the anti-human epithelial development issue receptor kind 2 (HER2) mAb trastuzumab as a foundation. Computationally chosen CDR-derived peptides had been first grafted onto two adjoining loops of the fibronectin kind III area (FN3) scaffold, yielding 80 D-FLAP candidates. After computational screening based mostly on their similarity to the parental mAb with regard to the conformation of paratope residues, two candidates had been chosen.
After additional analysis with ELISA, one D-FLAP with HYTTPP and GDGFYA peptides from CDR-L3 and CDR-H3 of the parental mAb, respectively, was discovered to bind HER2 with a dissociation fixed of 58 nM. Our methodology applies to numerous mAb medicine and permits the rational design of small protein options. This text is protected by copyright. All rights reserved.
FGL Peptide |
|||
| 073-36 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
APK peptide |
|||
| 076-81 | PHOENIX PEPTIDE | 200 μg | 199.8 EUR |
NEF peptide |
|||
| 076-83 | PHOENIX PEPTIDE | 500 μg | 140.4 EUR |
SHA peptide |
|||
| 076-84 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
YSY peptide |
|||
| 076-86 | PHOENIX PEPTIDE | 100 μg | 230.04 EUR |
TAT Peptide |
|||
| abx266559-1ml | Abbexa | 1 ml | 287.5 EUR |
TAT Peptide |
|||
| abx266559-200l | Abbexa | 200 µl | 237.5 EUR |
TAT peptide |
|||
| HY-P0282 | MedChemExpress | 10mg | 1398 EUR |
TAT peptide |
|||
| MBS5763704-10mg | MyBiosource | 10mg | 765 EUR |
TAT peptide |
|||
| MBS5763704-1mg | MyBiosource | 1mg | 190 EUR |
TAT peptide |
|||
| MBS5763704-5mg | MyBiosource | 5mg | 485 EUR |
TAT peptide |
|||
| MBS5763704-5x10mg | MyBiosource | 5x10mg | 3305 EUR |
TAT peptide |
|||
| TP1451-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: TAT peptide |
|||
TAT peptide |
|||
| TP1451-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: TAT peptide |
|||
TAT peptide |
|||
| TP1451-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: TAT peptide |
|||
TAT peptide |
|||
| TP1451-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: TAT peptide |
|||
TAT peptide |
|||
| TP1451-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: TAT peptide |
|||
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
| 024-57 | PHOENIX PEPTIDE | 200 μg | 86.4 EUR |
PSTAIR Peptide |
|||
| 070-61 | PHOENIX PEPTIDE | 500 μg | 129.6 EUR |
PGMtide Peptide |
|||
| 040-69 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Adjuvant Peptide |
|||
| 070-05 | PHOENIX PEPTIDE | 500 μg | 36.72 EUR |
Peptide-epsilon |
|||
| 058-22 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
Delicious Peptide |
|||
| 070-21 | PHOENIX PEPTIDE | 5 mg | 160.92 EUR |
proSex peptide (20-55) |
|||
| 040-30 | PHOENIX PEPTIDE | 100 μg | 355.32 EUR |
proSex peptide (28-55) |
|||
| 040-31 | PHOENIX PEPTIDE | 100 μg | 282.96 EUR |
proSex peptide (40-55) |
|||
| 040-32 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
| 007-60 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Peptide F-9 |
|||
| 038-06 | PHOENIX PEPTIDE | 200 μg | 58.32 EUR |
Sturgeon Peptide (137-158) |
|||
| 021-94 | PHOENIX PEPTIDE | 100 μg | 177.12 EUR |
Peptide Lv (Rat) |
|||
| 008-73 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
NGR Peptide 1 |
|||
| 025-74 | PHOENIX PEPTIDE | 200 μg | 184.68 EUR |
Anorexigenic Peptide |
|||
| 070-10 | PHOENIX PEPTIDE | 5 mg | 86.4 EUR |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
| 029-03 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
| 029-04 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
| 029-05 | PHOENIX PEPTIDE | 20 μg | 267.84 EUR |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
| 029-06 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
Bid BH3 peptide |
|||
| 025-87 | PHOENIX PEPTIDE | 1 mg | 170.64 EUR |
AF-16 Peptide |
|||
| 033-44 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Peptide Lv (Human) |
|||
| 008-71 | PHOENIX PEPTIDE | 100 μg | 405 EUR |
Peptide Lv (Mouse) |
|||
| 008-72 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
| 029-08 | PHOENIX PEPTIDE | 200 μg | 64.8 EUR |
ExE peptide M3mP6 |
|||
| 064-33 | PHOENIX PEPTIDE | 200 μg | 244.08 EUR |
Peptide B (Bovine) |
|||
| 024-56 | PHOENIX PEPTIDE | 200 μg | 81 EUR |
Peptide F (Bovine) |
|||
| 024-58 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
PLP Peptide (103-116) (Bovine) |
|||
| 070-14 | PHOENIX PEPTIDE | 5 mg | 140.4 EUR |
FMRF-Like Peptide |
|||
| 047-32 | PHOENIX PEPTIDE | 1 mg | 27 EUR |
Joining Peptide (Rat) |
|||
| 047-91 | PHOENIX PEPTIDE | 200 μg | 160.92 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
| 048-80 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
| 048-81 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
| 048-82 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Peptide T (4-8) |
|||
| 057-04 | PHOENIX PEPTIDE | 500 μg | 64.8 EUR |
Peptide T (5-8) |
|||
| 057-05 | PHOENIX PEPTIDE | 500 μg | 64.8 EUR |
Vasonatrin Peptide (VNP) |
|||
| 005-47 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Opioid Peptide Library |
|||
| L-002 | PHOENIX PEPTIDE | 58 peptides | 2691.36 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
| 064-01 | PHOENIX PEPTIDE | 200 μg | 108 EUR |
PGMtide Control Peptide |
|||
| 040-70 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Growth Blocking Peptide |
|||
| 046-92 | PHOENIX PEPTIDE | 100 μg | 255.96 EUR |
Neuron Specific Peptide |
|||
| 047-55 | PHOENIX PEPTIDE | 200 μg | 140.4 EUR |
Heparin Binding Peptide |
|||
| 025-47 | PHOENIX PEPTIDE | 500 μg | 102.6 EUR |
Gastrin Related Peptide |
|||
| 027-09 | PHOENIX PEPTIDE | 5 mg | 73.44 EUR |
Obesity Peptide Library |
|||
| L-003 | PHOENIX PEPTIDE | 160 peptides | 7267.32 EUR |
[D-Ala1]-Peptide T |
|||
| 057-02 | PHOENIX PEPTIDE | 5 mg | 282.96 EUR |
Peptide YY (PYY) (Human) |
|||
| 059-01 | PHOENIX PEPTIDE | 200 μg | 119.88 EUR |
Eledoisin Related Peptide |
|||
| 046-04 | PHOENIX PEPTIDE | 5 mg | 58.32 EUR |
proSex peptide (28-55) - EIA Kit |
|||
| EK-040-31 | PHOENIX PEPTIDE | 96 wells | 603.72 EUR |
Peptide F 1 (Lobster) |
|||
| 047-62 | PHOENIX PEPTIDE | 500 μg | 73.44 EUR |
Morphine Tolerance Peptide |
|||
| 050-13 | PHOENIX PEPTIDE | 1 mg | 102.6 EUR |
Phosphate Acceptor Peptide |
|||
| 058-24 | PHOENIX PEPTIDE | 500 μg | 73.44 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
| 064-07 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
| 047-39 | PHOENIX PEPTIDE | 200 μg | 444.96 EUR |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
| 047-40 | PHOENIX PEPTIDE | 500 μg | 214.92 EUR |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
| 047-42 | PHOENIX PEPTIDE | 200 μg | 444.96 EUR |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
| 047-43 | PHOENIX PEPTIDE | 500 μg | 214.92 EUR |
FGL Peptide - FAM Labeled |
|||
| FG-073-36A | PHOENIX PEPTIDE | 1 nmol | 405 EUR |
FGL Peptide - Cy3 Labeled |
|||
| FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | 672.84 EUR |
FGL Peptide - Cy5 Labeled |
|||
| FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | 756 EUR |
Pedal Peptide (Pep) (Aplysia) |
|||
| 047-61 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
ExE peptide M3mP6 mutant |
|||
| 064-35 | PHOENIX PEPTIDE | 200ug | 234.36 EUR |
ExE peptide M3mP6 mutant |
|||
| 064-37 | PHOENIX PEPTIDE | 200ug | 234.36 EUR |
FGL Peptide - FITC Labeled |
|||
| FG-073-36B | PHOENIX PEPTIDE | 1 nmol | 405 EUR |
AF-16 Peptide - Antibody |
|||
| H-033-44 | PHOENIX PEPTIDE | 100 μl | 336.96 EUR |
Schizophrenia Related Peptide |
|||
| 047-79 | PHOENIX PEPTIDE | 5 mg | 44.28 EUR |
Insulin B (22-25) Peptide |
|||
| 035-08 | PHOENIX PEPTIDE | 5 mg | 86.4 EUR |
Eosinophilotactic Peptide (AGSE) |
|||
| 070-28 | PHOENIX PEPTIDE | 5 mg | 27 EUR |
Eosinophilotactic Peptide (VGSE) |
|||
| 070-29 | PHOENIX PEPTIDE | 5 mg | 27 EUR |
Cell Penetrating ARF Peptide (26-44) |
|||
| 068-56 | PHOENIX PEPTIDE | 500 μg | 640.44 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
| RK-064-01 | PHOENIX PEPTIDE | 125 tubes | 932.04 EUR |
FGL Peptide - Biotin Labeled |
|||
| B-073-36 | PHOENIX PEPTIDE | 20 μg | 405 EUR |
Peptide F (Bovine) - Antibody |
|||
| H-024-58 | PHOENIX PEPTIDE | 50 μl | 238.68 EUR |
Brain Peptide (Bees) Library |
|||
| L-007 | PHOENIX PEPTIDE | 51 peptides | 6456.24 EUR |
Gastrointestinal Peptide Library |
|||
| L-006 | PHOENIX PEPTIDE | 200 peptides | 7267.32 EUR |
Peptide R / CXCR4 Antagonist |
|||
| 030-25 | PHOENIX PEPTIDE | 200 μg | 203.04 EUR |
PGMtide Peptide - FAM Labeled |
|||
| FG-040-69A | PHOENIX PEPTIDE | 5 nmol | 537.84 EUR |
PGMtide Peptide - Cy3 Labeled |
|||
| FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | 925.56 EUR |
[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
| 033-34 | PHOENIX PEPTIDE | 100 μg | 177.12 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
| H-064-07 | PHOENIX PEPTIDE | 50 μl | 238.68 EUR |
[D-Ala1]-Peptide T amide |
|||
| 057-03 | PHOENIX PEPTIDE | 500 μg | 140.4 EUR |
Peptide F (Bovine) - RIA Kit |
|||
| RK-024-58 | PHOENIX PEPTIDE | 125 tubes | 932.04 EUR |
Calmodulin Binding Peptide 1 |
|||
| 070-17 | PHOENIX PEPTIDE | 20 μg | 214.92 EUR |
Catch-Relaxing Peptide (CARP) |
|||
| 047-20 | PHOENIX PEPTIDE | 1 mg | 199.8 EUR |
FGL Peptide - Rhodamine Labeled |
|||
| FR-073-36 | PHOENIX PEPTIDE | 1 nmol | 537.84 EUR |
Peptide-Depleted Plasma (Rat) |
|||
| MB-099-02 | PHOENIX PEPTIDE | 2 ml | 119.88 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
| RK-064-07 | PHOENIX PEPTIDE | 125 tubes | 932.04 EUR |
Glycogenolysis-Inhibiting Peptide |
|||
| 023-63 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
Anti-Inflammatory Peptide 1 |
|||
| 004-01 | PHOENIX PEPTIDE | 200 μg | 27 EUR |
Anti-Inflammatory Peptide 2 |
|||
| 004-02 | PHOENIX PEPTIDE | 200 μg | 27 EUR |
Anti-Inflammatory Peptide 3 |
|||
| 004-03 | PHOENIX PEPTIDE | 200 μg | 27 EUR |
Urokinase-Derived Peptide A6 |
|||
| 025-12 | PHOENIX PEPTIDE | 500 μg | 129.6 EUR |
PGMtide Peptide - Biotin Labeled |
|||
| B-040-69 | PHOENIX PEPTIDE | 20 μg | 537.84 EUR |
Peptide 34 / GPR-54 Agonist |
|||
| 048-94 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
FGL Peptide - I-125 Labeled |
|||
| T-073-36 | PHOENIX PEPTIDE | 10 μCi | 1145.88 EUR |
Peptide-Depleted Plasma (Human) |
|||
| MB-099-01 | PHOENIX PEPTIDE | 2 ml | 119.88 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
| FG-064-07A | PHOENIX PEPTIDE | 1 nmol | 336.96 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
| T-064-01 | PHOENIX PEPTIDE | 10 μCi | 1145.88 EUR |
TAT Derivative, R9-Tat |
|||
| 068-27 | PHOENIX PEPTIDE | 500 μg | 370.44 EUR |
F3 Peptide / HMGN2 Fragment 3 |
|||
| 004-12 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Antimicrobial Trp-rich peptide |
|||
| 004-05 | PHOENIX PEPTIDE | 100 μg | 140.4 EUR |
Myosin Kinase Inhibiting Peptide |
|||
| 058-20 | PHOENIX PEPTIDE | 500 μg | 50.76 EUR |
Fibronectin CS1 Peptide (EILDVPST) |
|||
| 025-20 | PHOENIX PEPTIDE | 500 μg | 86.4 EUR |
Peptide YY (PYY) (3-36) (Human) |
|||
| 059-02 | PHOENIX PEPTIDE | 200 μg | 102.6 EUR |
Peptide YY (PYY) (Human) - Antibody |
|||
| H-059-01 | PHOENIX PEPTIDE | 100 μl | 469.8 EUR |
PGMtide Peptide - Rhodamine Labeled |
|||
| FR-040-69 | PHOENIX PEPTIDE | 5 nmol | 604.8 EUR |
Anti-Angiogenic Peptide Library |
|||
| L-008A | PHOENIX PEPTIDE | 88 peptides | 6067.44 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody |
|||
| G-064-01 | PHOENIX PEPTIDE | 400 μg | 438.48 EUR |
Peptide A / p60v-src (137-157) |
|||
| 058-21 | PHOENIX PEPTIDE | 500 μg | 135 EUR |
pro-Opionmelanocortin / J Peptide |
|||
| 022-22 | PHOENIX PEPTIDE | 200 μg | 177.12 EUR |
Cancer-Targeting Peptide Library |
|||
| L-015 | PHOENIX PEPTIDE | 289 peptides | 7253.28 EUR |
C28 optimized peptide 6 (Human) |
|||
| 073-82 | PHOENIX PEPTIDE | 100 μg | 235.44 EUR |
Peptide YY (PYY) (Human) - EIA Kit |
|||
| EK-059-01 | PHOENIX PEPTIDE | 96 wells | 617.76 EUR |
Peptide YY (PYY) (Human) - RIA Kit |
|||
| RK-059-01 | PHOENIX PEPTIDE | 125 tubes | 814.32 EUR |
Kemptide / Phosphate Acceptor Peptide |
|||
| 058-16 | PHOENIX PEPTIDE | 500 μg | 36.72 EUR |
Bioactive Secretory Peptide Library |
|||
| L-009 | PHOENIX PEPTIDE | 1016 peptides | 31350.24 EUR |
PACAP-Related Peptide (PRP) (Rat) |
|||
| 052-11 | PHOENIX PEPTIDE | 200 μg | 86.4 EUR |
Galanin-Like Peptide (GALP) (Rat) |
|||
| 026-52 | PHOENIX PEPTIDE | 100 μg | 282.96 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled |
|||
| T-064-07 | PHOENIX PEPTIDE | 10 μCi | 1145.88 EUR |
Virus Replication Inhibiting Peptide |
|||
| 070-85 | PHOENIX PEPTIDE | 5 mg | 160.92 EUR |
Crustacean Cardioactive Peptide (CCAP) |
|||
| 047-24 | PHOENIX PEPTIDE | 500 μg | 86.4 EUR |
Pri Peptide from sORF pri RNA |
|||
| 069-77 | PHOENIX PEPTIDE | 200 μg | 160.92 EUR |
Alzheimer Fingerprint Peptide Library |
|||
| L-011 | PHOENIX PEPTIDE | 85 peptides | 6529.68 EUR |
u PAR (84-95) Scrambled Peptide |
|||
| 072-47 | PHOENIX PEPTIDE | 200 μg | 177.12 EUR |
PACAP-Related Peptide (PRP) (Human) |
|||
| 052-10 | PHOENIX PEPTIDE | 200 μg | 86.4 EUR |
Scrambled Control for Pri Peptide |
|||
| 069-78 | PHOENIX PEPTIDE | 200 μg | 160.92 EUR |
FMRF-Like Peptide (Helix aspersa) |
|||
| 047-31 | PHOENIX PEPTIDE | 1 mg | 27 EUR |
Annexin A1 Binding Peptide, IF7CRR |
|||
| 025-72 | PHOENIX PEPTIDE | 200 μg | 184.68 EUR |
Galanin-Like Peptide (GALP) (Human) |
|||
| 026-51 | PHOENIX PEPTIDE | 100 μg | 230.04 EUR |
Gastrin Releasing Peptide (GRP) (Rat) |
|||
| 027-32 | PHOENIX PEPTIDE | 100 μg | 160.92 EUR |
Kinetensin / Neurotensin Related Peptide |
|||
| 048-01 | PHOENIX PEPTIDE | 500 μg | 58.32 EUR |
Small Cardioactive Peptide A (SCPA) |
|||
| 047-76 | PHOENIX PEPTIDE | 1 mg | 64.8 EUR |
Gastrin Releasing Peptide (GRP) (Frog) |
|||
| 027-33 | PHOENIX PEPTIDE | 100 μg | 160.92 EUR |
Epidermal Growth Factor Receptor Peptide (985-996) |
|||
| 030-05 | PHOENIX PEPTIDE | 500 μg | 102.6 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody |
|||
| G-064-07 | PHOENIX PEPTIDE | 400 μg | 438.48 EUR |
Galanin-Like Peptide (GALP) (Porcine) |
|||
| 026-50 | PHOENIX PEPTIDE | 100 μg | 230.04 EUR |
Gastrin Releasing Peptide (GRP) (Human) |
|||
| 027-07 | PHOENIX PEPTIDE | 200 μg | 119.88 EUR |
Gastrin Releasing Peptide (GRP) (Mouse) |
|||
| 027-40 | PHOENIX PEPTIDE | 100 μg | 160.92 EUR |
PGMtide Control Peptide - FAM Labeled |
|||
| FG-040-70A | PHOENIX PEPTIDE | 5 nmol | 537.84 EUR |
Growth Blocking Peptide - FAM Labeled |
|||
| FG-046-92A | PHOENIX PEPTIDE | 1 nmol | 336.96 EUR |
PGMtide Control Peptide - Cy3 Labeled |
|||
| FC3-040-70 | PHOENIX PEPTIDE | 1 nmol | 925.56 EUR |
Chop-Suey / Variety Peptide Library |
|||
| L-001 | PHOENIX PEPTIDE | 238 peptides | 7400.16 EUR |
T3 Peptide / Tumstatin (69-88) (Human) |
|||
| 016-50 | PHOENIX PEPTIDE | 100 μg | 255.96 EUR |
T7 Peptide / Tumstatin (74-98) (Human) |
|||
| 016-51 | PHOENIX PEPTIDE | 100 μg | 255.96 EUR |
Peptide YY (PYY) (1-36)-Gly (Human) |
|||
| 059-07 | PHOENIX PEPTIDE | 100 μg | 295.92 EUR |
Peptide YY (PYY) (3-36)-Gly (Human) |
|||
| 059-08 | PHOENIX PEPTIDE | 100 μg | 282.96 EUR |
Peptide YY (PYY) (2-36)-Gly (Human) |
|||
| 059-11 | PHOENIX PEPTIDE | 100 μg | 267.84 EUR |
Peptide YY (PYY) (4-36)-Gly (Human) |
|||
| 059-12 | PHOENIX PEPTIDE | 100 μg | 267.84 EUR |
Hypocholesterolemic Peptide / IIAEK (Bovine) |
|||
| 028-37 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
Fractalkine Chemokine Domain peptide (41-52) (Human) |
|||
| 026-82 | PHOENIX PEPTIDE | 200 μg | 160.92 EUR |
Fractalkine Chemokine Domain peptide (53-60) (Human) |
|||
| 026-83 | PHOENIX PEPTIDE | 200 μg | 135 EUR |
Fractalkine Chemokine Domain peptide (60-71) (Human) |
|||
| 026-84 | PHOENIX PEPTIDE | 200 μg | 160.92 EUR |
FMRF-Like Peptide ( Lymnae stagnalis) |
|||
| 047-30 | PHOENIX PEPTIDE | 5 mg | 129.6 EUR |
Peptide F (Bovine) - I-125 Labeled |
|||
| T-024-58 | PHOENIX PEPTIDE | 10 μCi | 1145.88 EUR |
Kappa-Receptor, C-terminal peptide |
|||
| 002-98 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
Angiotensin II - constrained peptide 1 |
|||
| 004-09 | PHOENIX PEPTIDE | 500 μg | 165.24 EUR |
VEGFR binding peptide KH / QKRKRKKSRKKH |
|||
| 007-58 | PHOENIX PEPTIDE | 100 μg | 158.76 EUR |
Delta-Sleep-Inducing Peptide (DSIP) |
|||
| 070-22 | PHOENIX PEPTIDE | 500 μg | 27 EUR |
[Thr5]-Speract / Sperm Activating Peptide |
|||
| 070-71 | PHOENIX PEPTIDE | 1 mg | 114.48 EUR |